Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial-Reference-Cited by-同舟云学术

Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial

Published:2023-12 Issue: Volume: Page:
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Matasar Matthew^ORCID,Bartlett Nancy L.,Shadman Mazyar,Budde Lihua E.,Flinn Ian,Gregory Gareth P.,Kim Won Seog,Hess Georg,El-Sharkawi Dima^ORCID,Diefenbach Catherine S.,Huang Huang,To Iris,Parreira Joana^ORCID,Wu Mei,Kwan Antonia,Assouline Sarit

Funder

F. Hoffmann-La Roche Ltd

F. Hoffmann-La Roche

Genentech

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference22 articles.

1. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies;Sun;Sci Transl Med,2015

2. Pharmacodynamic effects and immune correlates of response to the CD20/CD3 bispecific antibody mosunetuzumab in relapsed or refractory non-Hodgkin lymphoma;Hernandez;Blood,2019

3. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study;Budde;J Clin Oncol,2021

4. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study;Budde;Lancet Oncol,2022

5. Roche Pharma AG. Summary of product characteristics: Lunsumio 1 mg concentrate for solution for infusion and Lunsumio 30 mg concentrate for solution for infusion. 2023. Available from: https://www.ema.europa.eu/en/documents/product-information/lunsumio-epar-product-information_en.pdf accessed November 29, 2023.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mosunetuzumab for the treatment of follicular lymphoma;Expert Opinion on Biological Therapy;2024-09-11

2. Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data;International Journal of Molecular Sciences;2024-09-09

3. Current and future therapies for follicular lymphoma;Experimental Hematology & Oncology;2024-08-22

4. Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis;Blood Advances;2024-07-01

5. Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma;American Society of Clinical Oncology Educational Book;2024-06